Comparison of Tab.Labetalol and Tab.Nifedipine for Management of Postpartum Hypertension

Postnatal Hypertension Clinical Trial

Official title:

Comparison of Oral Labetalol and Oral Nifedipine for Postpartum Hypertension Management

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02426177
• Other study ID #: DowUHS
• Status: Not yet recruiting
• Phase: Phase 3
• First received: April 21, 2015
• Last updated: April 23, 2015
• Start date: May 2015
• Est. completion date: December 2016

Study information

• Verified date: April 2015
• Source: Dow University of Health Sciences
• Contact: fariha javed, mbbs
• Phone: 923009298708
• Email: farihajaved207[@]yahoo.com
• Is FDA regulated: No
• Health authority: Pakistan: Drug Regulatory Authority of Pakistan
• Study type: Interventional

Clinical Trial Summary

To compare effectiveness of oral labetalol and oral nifedipine for management of postpartum hypertension.

Description:

A comparison of oral labetalol and oral nifedipine for management of postpartum hypertension. Which drug is more effective in lowering blood pressures in patient with postpartum hypertension.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 98
• Est. completion date: December 2016
• Est. primary completion date: May 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 20 Years to 48 Years

Eligibility

Inclusion Criteria:

• all women with postpartum hypertension as a continuation of pregnancy induced hypertension,eclampsia, pre-eclampsia or new onset de-novo postpartum hypertension,of any parity.

• age group between 18-48.

• after informed consent.

Exclusion Criteria:

• all women with chronic hypertension, uncontrolled and un treated medical disorders will be excluded.

• conditions in which drugs labetalol and nifedipine is contraindicated.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hypertension
• Postnatal Hypertension

Intervention

Drug:
• Labetalol
anti-hypertensive agents
• Nifedipine
calcium channel blocker ,for lowering blood pressure

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Dow University of Health Sciences

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood Pressure less than 140/90 mm of hg	less than 140/90 mm of hg	24 hours	No